Irvine-based medical device maker Endologix Inc. said Thursday that its accountant expressed “substantial doubt” about its ability to continue operating, according to a regulatory filing.
PricewaterhouseCoopers LLP cited Endologix’s history of losses for its concern.
The news sent Endologix shares down 7.3% to $4.60 in afterhours trading.
Endologix, which makes minimally invasive devices to treat aneurysms, said it expects to have enough money to fund its operations through the end of the year.
Endologix Chief Executive Paul McCormick said that if appropriate, it could consider alternatives for additional financing, either through selling shares or getting loans.
Endologix’s Securities and Exchange Commission filing noted that the device maker has accumulated losses of $99 million since it was founded in 1992.
